Blast and Cruise: What It Is and the Real Risks
Cycle Design · 6 min read · Updated on May 23, 2026
Blast and cruise — often shortened to B&C — names a practice that sits apart from a classic cycle: you alternate "blast" phases (cycle at supraphysiological doses) with "cruise" phases (physiological dose, equivalent to TRT), without ever stopping exogenous testosterone. No PCT, no off-period. It is a choice that turns an occasional cycle into a lifelong hormonal commitment.
This guide describes the structure, the consequences and the risks of B&C. It does not recommend it nor condemn it — it lays out what it actually is, and what anyone considering it should integrate. For the comparable frame of a classic cycle, see the how to design a steroid cycle pillar; for medical TRT, see TRT protocol guide.
Definition: blast and cruise
Blast and cruise alternates two phases, never stopping the testosterone.
- The blast: a 10 to 16-week phase at a supraphysiological dose, similar to a classic cycle. Often a high testosterone base + an added compound (deca, masteron, sometimes tren).
- The cruise: a phase of several weeks to several months at a physiological dose, typically 100 to 200 mg of testosterone enanthate per week — equivalent to a TRT protocol.
The crucial difference with a classic cycle: there is no PCT and no testosterone-free period. The HPTA is suppressed permanently; natural testosterone will not come back as long as the B&C lasts — and in many cases, will not come back after either [1].
Structural difference with a classic cycle
| Criterion | Classic cycle | Blast and cruise |
|---|---|---|
| Testosterone-free periods | Yes (PCT + off) | No, never |
| PCT | Mandatory at cycle end | Absent by construction |
| Target HPTA recovery | Yes, after each cycle | No, permanent suppression assumed |
| Natural production restored | PCT target | Explicitly forgone |
| Natural fertility | Preserved off-cycle | Compromised as long as B&C lasts (and often beyond) |
| Frame of reference | Seasonal (1 to 2 cycles/year) | Continuous, lifelong commitment |
| Medical supervision | Wanted, sometimes missing | Near-mandatory to stay framed |
On the purely hormonal side, a B&C practitioner sits in the same state as a patient on lifelong TRT — with additional supraphysiological phases on top. The testosterone supplementation is not designed to ever stop.
Why some practitioners run B&C
Arguments people make for it
- Avoid the post-PCT troughs and the fatigue that follows every classic cycle.
- Hold on to a larger share of cycle gains — PCT always gives some back.
- Simplify planning: no more PCT windows, no more "time on = time off" math.
- Acknowledge that past a certain number of cumulative cycles, natural recovery does not happen anyway — so own it.
Arguments against
- Definitive forfeit of endogenous testosterone production — hormonal dependence becomes permanent.
- Near-systematic infertility during B&C, partially reversible in some, irreversible in others (the long-term data is thin).
- Major cardiovascular accumulation: chronically elevated hematocrit, degraded lipid profile, left ventricular hypertrophy associated with repeated supraphysiological cycles. Over 20-30 years, the consequences are poorly documented but concerning [3].
- No window to let certain markers (liver, lipids) return to baseline.
- Lifelong commitment to sourcing, cost, and side-effect management without a pause.
Who actually runs B&C
B&C is widespread in several sub-populations: professional bodybuilders (where coming off has become rare), elite "tested" or untested powerlifters, some lifters past 30-35 who find their HPTA recovery becoming difficult after several cumulative cycles. It also shows up, more problematically, in amateurs who slide into B&C out of PCT fatigue rather than out of a deliberate decision.
Monitoring: non-negotiable
Without a pause, there is no natural window for certain markers to return to baseline. Monitoring becomes the central element of B&C management. Every 3 to 6 months minimum, more frequent during blast phases [6].
- Hematocrit: permanent testosterone chronically elevates it. Past 54-55%, blood donation becomes a regular option. See hematocrit and steroids.
- Lipid panel (HDL/LDL/ApoB): chronic degradation is expected. Cardiology follow-up advised after a few years of B&C.
- Blood pressure: regular at-home measurement, antihypertensive treatment if needed.
- Estradiol: fine-grained management — an AI may be needed at a modulated dose depending on the phase.
- Renal and hepatic function: regular panels, especially during blasts.
- Cardiac markers: cardiac ultrasound every 1-2 years to monitor left ventricular hypertrophy, strongly associated with chronic steroid use.
The detailed schedule sits in the blood work on cycle guide; the specific hormonal markers in hormonal markers on cycle.
Getting off B&C: is it possible?
Coming off a B&C run that has lasted several years is possible, but with a markedly lower probability of natural recovery than after an occasional cycle. The exit protocol relies on the same tools as a classic PCT — SERM, sometimes preparatory HCG — but extended in time (several months). Follow-up by an endocrinologist familiar with the topic is strongly recommended: self-managing the exit is risky [5].
The other option, more pragmatic for many, is to move from B&C to a medically-supervised lifelong TRT: the supraphysiological dose is dropped, but the physiological-dose testosterone supplementation is kept for life. See TRT protocol guide.
Frequently asked questions
Is B&C equivalent to lifelong TRT?
On HPTA suppression and dependence on exogenous supply: yes. On doses and cardiovascular risk: no. Medical TRT aims to restore testosterone to a physiological level to treat hypogonadism — the dose and blood markers are calibrated to stay inside the normal range. B&C alternates physiological phases (cruise) with supraphysiological phases (blast) — that second phase is what adds the cumulative risks specific to a classic cycle, repeated twice a year without a pause.
Can you return to natural testosterone production after a long B&C?
Possible, never guaranteed. The longer the B&C lasted (years), the lower the probability of full recovery. Some users partially recover after an extended SERM + HCG protocol; others retain a persistent hypogonadism that requires lifelong TRT [1]. Without medical follow-up, the exit is risky — this is one of the situations where self-management clearly shows its limits.
After how many classic cycles does the community consider B&C?
There is no objective threshold. Some practitioners never switch; others consider B&C after 4 to 6 cumulative cycles when post-PCT recovery becomes markedly harder. The decision should not be made on the back of one rough PCT but after several post-PCT hormonal panels showing durably incomplete HPTA recovery — ideally with a medical opinion. A default switch = wrong reason.
Sources
Studies and scientific publications this guide relies on.
- Rasmussen JJ, Selmer C, Østergren PB, et al. (2016). Former Abusers of Anabolic Androgenic Steroids Exhibit Decreased Testosterone Levels and Hypogonadal Symptoms Years after Cessation: A Case-Control Study. PLoS One. doi: 10.1371/journal.pone.0161208
Étude cas-témoin chez d'anciens utilisateurs d'AAS au long cours : taux de testostérone plus bas et symptômes hypogonadiques persistants des années après l'arrêt — illustration de la suppression durable consécutive à une exposition cumulative élevée.
- Smit DL, Buijs MM, de Hon O, et al. (2021). Disruption and recovery of testicular function during and after androgen abuse: the HAARLEM study. Human Reproduction. doi: 10.1093/humrep/deaa366
Étude prospective HAARLEM (100 utilisateurs amateurs) : à 12 mois post-arrêt, le volume testiculaire et la spermatogenèse restent en deçà du baseline, particulièrement chez les utilisateurs chroniques avec une exposition cumulative élevée — profil typique d'une pratique B&C antérieure.
- Baggish AL, Weiner RB, Kanayama G, et al. (2017). Cardiovascular Toxicity of Illicit Anabolic-Androgenic Steroid Use. Circulation. doi: 10.1161/CIRCULATIONAHA.116.026945
Étude transversale (86 utilisateurs AAS au long cours vs 54 non-utilisateurs) : dysfonction systolique et diastolique du ventricule gauche, athérosclérose coronaire accélérée, profil lipidique fortement dégradé chez les utilisateurs chroniques.
- Pope HG Jr, Wood RI, Rogol A, et al. (2014). Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocrine Reviews. doi: 10.1210/er.2013-1058
Énoncé scientifique de l'Endocrine Society : usage prolongé de stéroïdes androgéniques à doses supraphysiologiques (qu'il s'agisse de cycles répétés ou de B&C) associé à un risque cardiovasculaire, hépatique, hormonal et psychiatrique cumulé.
- Coward RM, Rajanahally S, Kovac JR, et al. (2013). Anabolic steroid induced hypogonadism in young men. Journal of Urology. doi: 10.1016/j.juro.2013.06.010
Série de cas d'hommes jeunes présentant un hypogonadisme induit par les stéroïdes (ASIH) : suppression persistante de l'axe HPT après l'arrêt, parfois durable, justifiant le recours à une TRT à vie chez certains.
- Smit DL, Bond P, de Ronde W (2022). Health effects of androgen abuse: a review of the HAARLEM study. Current Opinion in Endocrinology, Diabetes and Obesity. doi: 10.1097/MED.0000000000000759
Synthèse narrative des résultats HAARLEM : les modifications cardiovasculaires (tension, hématocrite, profil lipidique) constituent le principal facteur de risque à long terme dans l'usage chronique d'AAS, et appellent une stratégie de réduction des risques plutôt qu'une approche binaire.
Guides liés
Molécules citées
Calculateurs utiles
Track your cycle with real data
Daily journal, 52 compounds, blood work and AI analysis — to apply what you just read and track results cycle after cycle.
Free 5-day trial — no credit card